Furuta Akira, Lellouche Nicolas, Mouillet Gauthier, Dhanjal Tarvinder, Gilard Martine, Laskar Marc, Eltchaninoff Helene, Fajadet Jean, Iung Bernard, Donzeau-Gouge Patrick, Leprince Pascal, Leuguerrier Alain, Prat Alain, Dubois-Rande Jean-Luc, Teiger Emmanuel
Cardiology Department, Hôpital Henri-Mondor, Assistance-Publique-Hôpitaux-de-Paris, 51 Avenue du Maréchal de Lattre de Tassigny, 94000 Creteil, France.
Cardiology Department, Hôpital Henri-Mondor, Assistance-Publique-Hôpitaux-de-Paris, 51 Avenue du Maréchal de Lattre de Tassigny, 94000 Creteil, France.
Int J Cardiol. 2016 May 1;210:72-9. doi: 10.1016/j.ijcard.2016.02.073. Epub 2016 Feb 13.
The development of new onset atrial fibrillation (NOAF) post-transcatheter aortic valve implantation (TAVI) is common and may be associated with an adverse prognosis. This study seeks to identify incidence, predictors, and impact of NOAF post-TAVI.
From the multicenter study of the French national transcatheter aortic valve implantation registry, FRANCE 2, a total of 1959 patients with sinus rhythm prior to TAVI were enrolled into this study. The incidence of post-TAVI NOAF, predictors of development of NOAF and impact on 30-day and 1-year-mortalities were assessed.
Of the 1959 TAVI patients (mean-age: 82.6 ± 7.5 years, mean-logistic-EuroSCORE: 21.8 ± 14.3), 149 (7.6%) developed NOAF with the remaining 1810 (92.4%) control patients demonstrating no evidence of AF as defined by the Valve Academic Research Consortium (VARC). Advanced age and major and life-threatening bleeding were independent predictors of NOAF (95% CI: 0.93-0.99; p=0.006, 95% CI: 1.58-4.00; p<0.001, 95% CI: 1.09-3.75; p=0.025, respectively). A trend towards a higher incidence of major and life-threatening bleeding was observed in the patients undergoing TAVI via the transapical (TA)-approach compared with the transfemoral (TF)-approach. Both 30-day and cumulative 1-year-mortalities were significantly higher in patients with NOAF compared to patients without NOAF (3.0% vs. 7.4%; p=0.005, 9.1% vs. 20.8%; p<0.001, respectively). In addition, NOAF was an independent predictor of 30-day and 1-year-mortalities (HR: 2.16; 95% CI: 1.06-4.41; p=0.033, HR: 2.12; 95% CI: 1.42-3.15; p<0.001, respectively).
Advanced age and major and life-threatening bleeding were independently associated with increased incidence of NOAF, which itself was an independent predictor of 30-day and 1-year-mortalities. With regards to the various transcatheter approaches, a trend towards a higher incidence of major and life-threatening bleeding was observed only with the TA-approach.
经导管主动脉瓣植入术(TAVI)后新发房颤(NOAF)很常见,且可能与不良预后相关。本研究旨在确定TAVI后NOAF的发生率、预测因素及其影响。
从法国国家经导管主动脉瓣植入注册研究FRANCE 2的多中心研究中,共纳入1959例TAVI术前为窦性心律的患者。评估TAVI后NOAF的发生率、NOAF发生的预测因素以及对30天和1年死亡率的影响。
在1959例TAVI患者中(平均年龄:82.6±7.5岁,平均逻辑欧洲心脏手术风险评估系统评分:21.8±14.3),149例(7.6%)发生了NOAF,其余1810例(92.4%)对照患者未出现瓣膜学术研究联盟(VARC)定义的房颤证据。高龄以及严重和危及生命的出血是NOAF的独立预测因素(95%置信区间:0.93 - 0.99;p = 0.006,95%置信区间:1.58 - 4.00;p < 0.001,95%置信区间:1.09 - 3.75;p = 0.025)。与经股动脉(TF)途径相比,经心尖(TA)途径进行TAVI的患者中,严重和危及生命的出血发生率有升高趋势。与无NOAF的患者相比,有NOAF的患者30天和1年累计死亡率均显著更高(3.0%对7.4%;p = 0.005,9.1%对20.8%;p < 0.001)。此外,NOAF是30天和1年死亡率的独立预测因素(风险比:2.16;95%置信区间:1.06 - 4.41;p = 0.033,风险比:2.12;95%置信区间:1.42 - 3.15;p < 0.001)。
高龄以及严重和危及生命的出血与NOAF发生率增加独立相关,而NOAF本身是30天和1年死亡率的独立预测因素。关于各种经导管途径,仅在TA途径中观察到严重和危及生命的出血发生率有升高趋势。